Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.65
Bid: 2.50
Ask: 2.80
Change: -0.05 (-1.85%)
Spread: 0.30 (12.00%)
Open: 2.70
High: 2.70
Low: 2.65
Prev. Close: 2.70
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

ValiRx Shares Fall After Bracknor Converts GBP200,000 Of Loan Notes (ALLISS)

Tue, 19th Apr 2016 14:45

LONDON (Alliance News) - ValiRx PLC shares dropped on Tuesday after the company said it has issued new shares to Bracknor after it converted GBP200,000 of its convertible loan notes into shares.

As a result, ValiRx has issued 2.7 million new shares in the company to Bracknor at 7.4 pence each, representing around 5.6% of ValiRx's enlarged issued share capital.

Bracknor has around GBP90,000 of convertible loan notes left to convert following the transaction.

ValiRx shares were down 9.2% to 8.40 pence per share on Tuesday afternoon.

By Joshua Warner; joshuawarner@alliancenews.com; @JoshAlliance

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
5 Feb 2015 08:18

ValiRx Buys Finnish Gene Expression And Biomarker Technology

Read more
15 Jan 2015 10:36

ValiRx Expects First VAL201 Results In 1st Quarter; VAL401 Progresses

Read more
13 Nov 2014 09:47

ValiRx Enters Collaboration Agreement For GeneICE Development

Read more
3 Nov 2014 11:09

ValiRx VAL201 PhaseI/II Trial Progressing In Line With Plan

Read more
14 Oct 2014 09:22

ValiRx VAL201 Phase I/II Trial Ready To Begin Recruitment

Read more
8 Oct 2014 15:31

ValiRx Completes YA Global Master Equity Swap Deal Early

Read more
2 Sep 2014 09:27

Valirx's lung cancer treatment receives positive results

Valirx, the developer and producer of technology used in oncology therapeutics, has received positive results from the studies on one of its lung cancer treatments. The studies on treatment VAL401 were carried out by Valiseek, Valirx's joint venture company with Tangent Reprofiling, and demonstrate

Read more
2 Sep 2014 07:26

UK MORNING BRIEFING: Weir Group Leads Firm London Market On Upgrade

Read more
2 Sep 2014 06:40

ValiRx Says Preclinical Trials For VAL401 In Lung Cancer Positive

Read more
19 Aug 2014 10:08

ValiRx Narrows Half-Year Loss On Lower Costs, Progresses Pipeline

Read more
4 Aug 2014 11:12

UK MIDDAY BRIEFING: HSBC Results Below Expectations

Read more
4 Aug 2014 10:49

UK WINNERS & LOSERS: HSBC And Intertek Rise Despite Lower Profit

Read more
4 Aug 2014 07:36

ValiRx Gets Authorisation For VAL201 Trials, Shares Jump

Read more
4 Aug 2014 07:34

UK MORNING BRIEFING: UK Shares Flat Ahead Of HSBC Results

Read more
24 Jun 2014 09:23

DIRECTOR DEALINGS: ValiRx Directors Buy 5.3 Million Shares

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.